A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder
Psychiatry Research, 07/23/09
- Kahbazi M et al. – The results of this study indicate that modafinil significantly improved symptoms of ADHD, was well tolerated, and may open a new window in the treatment of children with ADHD.
- Patients were 46 outpatients, children (35 boys and 11 girls) between the ages of 6 and 15 who clearly met the DSM–IV–TR diagnostic criteria for ADHD.
- All study subjects were randomly assigned to receive treatment with modafinil in a film–coated tablet, 200–300 mg/day, depending on weight (200 mg/day for <30 kg and 300 mg/day for >30 kg) (group 1) or placebo (group 2) for a 6–week double–blind, randomized clinical trial.
- The principal outcome measure was the Teacher and Parent ADHD Rating Scale–IV.
- Patients were assessed by a psychiatrist at baseline, 14, 28 and 42 days after the medication started.
- At 6 weeks, modafinil produced a significantly better outcome on the Parent and Teacher Rating Scale scores than placebo.
- Decreased appetite was observed more often in the modafinil group.
No comments:
Post a Comment